Sequential Dual-Composition Lipid Nanoparticles for Stable iPSC Production

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing methods for producing induced pluripotent stem cells using viral vectors face risks of vector persistence and incomplete reprogramming, while lipofection methods struggle with stability and homogeneity.

Innovation Solution

A method utilizing two types of lipid nanoparticles with different lipid component compositions is employed, where the first nanoparticle is used to initiate reprogramming and the second nanoparticle continues the process, ensuring efficient and complete reprogramming without viral risks.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If viral vectors are used to express reprogramming factors, then reprogramming can be achieved, but vector persistence and viral contamination risks occur

Engineering Contradiction:

Improvereprogramming efficiencyVSAvoidvector persistence risk

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts the harmful viral vector component and replaces it with a non-viral lipid nanoparticle delivery system. The lipid nanoparticles deliver reprogramming factors (mRNA or proteins) without integrating into the host genome, thereby eliminating vector persistence and viral contamination risks while maintaining reprogramming efficiency.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent introduces lipid nanoparticles as an intermediary carrier to deliver reprogramming factors into cells. This intermediary system avoids direct viral integration by using transient, non-integrating lipid-based delivery, thus resolving the contradiction between achieving reprogramming and avoiding vector persistence.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Object-affected harmful factors

If lipofection is used to deliver reprogramming factors, then viral risks are eliminated, but stable and homogeneous production is difficult to achieve

Engineering Contradiction:

Improveviral contamination riskVSAvoidproduction homogeneity

Core Design Contradiction:

Object-affected harmful factorsVSManufacturing precision

Solution Approach 1:

The patent optimizes parameters of the lipid nanoparticles including lipid composition ratios, particle size, charge characteristics, and delivery timing. By carefully controlling these parameters, the system achieves both non-viral safety and homogeneous, stable production of induced pluripotent stem cells with consistent reprogramming outcomes.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent employs composite lipid nanoparticle formulations combining different lipid components (e.g., cationic lipids, neutral lipids, cholesterol, and PEGylated lipids) to create a delivery system that simultaneously ensures efficient reprogramming factor delivery, cellular uptake, and homogeneous cell population outcomes without viral risks.

Inventive Principle:

Principle #40Composite materials

3Device complexity

If single lipid nanoparticle is used for reprogramming, then simplicity is maintained, but reprogramming completion is insufficient

Engineering Contradiction:

Improvedelivery system simplicityVSAvoidreprogramming completeness

Core Design Contradiction:

Device complexityVSReliability

Solution Approach 1:

The patent segments the reprogramming process into multiple stages using sequential lipid nanoparticle deliveries. Different lipid nanoparticle formulations are applied at different time points to deliver reprogramming factors in phases, ensuring complete and robust reprogramming while maintaining relative simplicity through a systematic multi-step protocol.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent implements continuous or repeated application of lipid nanoparticles to maintain sustained reprogramming factor expression. By applying lipid nanoparticles multiple times at intervals, the system ensures continuous reprogramming action that completes the complex differentiation process reliably, overcoming the limitations of single-dose approaches.

Inventive Principle:

Principle #20Continuity of useful action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach allows for stable and homogeneous production of induced pluripotent stem cells by maintaining and enhancing the effect of reprogramming factors, preventing incomplete reprogramming and ensuring efficient cell conversion.

Implementation Method 1

bringing a first lipid nanoparticle into contact at least once with a fibroblast, followed by bringing a second lipid nanoparticle into contact at least once with the fibroblast

Methodology Applied

Scientific EffectLipid nanoparticle membrane fusion:

Implementation Method 2

The lipid component composition ratios of the first lipid nanoparticle and the second nanoparticle are different from each other

Methodology Applied

Scientific EffectEndocytosis:

Data Source

PatentUS20250223570A1Method for producing induced pluripotent stem cell, nucleic acid introduction carrier and kit

Publication Date: 2025.07.10 KK TOSHIBA

AI summary

According to one embodiment, a method is for producing an induced pluripotent stem cell. The method includes bringing a first lipid nanoparticle into contact at least once with a fibroblast, followed by bringing a second lipid nanoparticle into contact at least once with the fibroblast. The first lipid nanoparticle and the second lipid nanoparticle each contain a reprogramming factor. The lipid component composition ratios of the first lipid nanoparticle and the second lipid nanoparticle are different from each other.